This is a routine preclinical data announcement with no immediate stock-moving catalyst. Monitor for potential partnership announcements during the BIO International Convention (June 22-25) or future clinical data releases.
Price Chart
Executive Summary
VERAXA Biotech announced in vitro proof-of-concept data for its BiTAC-ADC platform, demonstrating selective killing of breast cancer cells in 3D tumor spheroids. The company will present at the BIO International Convention next week to discuss partnering opportunities. This is an early-stage preclinical update with no financial data or near-term catalyst.
Key Facts
- VERAXA generated new in vitro proof-of-concept data validating its BiTAC-ADC platform.
- BiTAC-ADCs showed dose-dependent cytotoxicity in 3D breast cancer spheroids while discriminating between cancer and healthy cells.
- Company will attend BIO International Convention in San Diego, June 22-25, 2026, to discuss partnering opportunities.
- VERAXA recently listed on NASDAQ (earlier this month).
Financial Impact
Not specified
Risk Factors
- Platform is at early preclinical stage; no in vivo or clinical data yet.
- Off-tumor toxicity may still emerge in animal models.
- Need for additional validation and potential partnering to advance development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3314047 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 6-K | $1.11 | awaiting T+20 | — | $0.9800 (−11.71%) |
Sep 4, 2026 7w ago | 6-K | $1.76 $1.13 | ▼ −35.80% | ▼ −36.40% | $0.9800 (−44.32%) |
Sep 4, 2026 7w ago | Press Release | $1.76 $1.13 | ▼ −35.80% | ▼ −36.40% | $0.9800 (−44.32%) |
Aug 24, 2026 9w ago | 6-K | $1.78 $1.46 | ▼ −17.98% | ▼ −17.99% | $0.9800 (−44.94%) |
Aug 10, 2026 11w ago | EFFECT | $1.85 $1.60 | ▲ +13.51% | ▲ +12.60% | $0.9800 (+47.03%) |
Aug 7, 2026 11w ago | EFFECT | $1.99 $1.76 | ▲ +11.56% | ▲ +11.16% | $0.9800 (+50.75%) |
Jul 31, 2026 12w ago | F-1 | $1.83 $1.35 | ▲ +26.23% | ▲ +27.47% | $0.9800 (+46.45%) |
Jul 31, 2026 12w ago | F-1 | $1.83 $1.35 | ▲ +26.23% | ▲ +27.47% | $0.9800 (+46.45%) |
Jul 27, 2026 13w ago | 6-K | $1.98 $1.73 | ▼ −12.63% | ▼ −16.01% | $0.9800 (−50.51%) |
Jul 27, 2026 13w ago | 6-K | $2.01 $1.78 | ▼ −11.44% | ▼ −14.74% | $0.9800 (−51.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers